This huge response advantage in the low-AMscore subgroup, independent of other biomarkers, was further validated in the UTC, melanoma, and NSCLC cohorts, regardless of stratification according to TMB, TNB, PD-L1 expression on tumor cells, PD-L1 expression on immune cells (IC), or immune phenotype. This evidence concerns the gene CD274 and neoplasm.